Patents by Inventor Thomas Chittenden

Thomas Chittenden has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Anti-CD123 antibodies and conjugates and derivatives thereof
    Patent number: 11897961
    Abstract: The present invention generally relates to antibodies, antigen-binding fragments thereof, polypeptides, and immunoconjugates that bind to CD123 antigen (the ? chain of the interleukine 3 receptor, or IL-3R?). The present invention also relates to methods of using such CD123-binding molecules for diagnosing and treating diseases, such as B-cell malignancies.
    Type: Grant
    Filed: April 1, 2022
    Date of Patent: February 13, 2024
    Assignee: IMMUNOGEN, INC.
    Inventors: Yelena Kovtun, Daniel J. Tavares, Lingyun Rui, Thomas Chittenden
  • Biparatopic FR-alpha antibodies and immunoconjugates
    Patent number: 11834498
    Abstract: The present disclosure provides biparatopic antibodies comprising polypeptides that bind to folate receptor alpha (FR?) compositions comprising such biparatopic antibodies. In a specific aspect, the biparatopic antibodies bind to FR? and modulate FR? activity. The present disclosure also provides methods for treating disorders, such as cancer, by administering a biparatopic antibody that specifically binds to FR? and modulates FR? activity.
    Type: Grant
    Filed: June 10, 2022
    Date of Patent: December 5, 2023
    Assignee: ImmunoGen, Inc.
    Inventors: Olga Ab, Neeraj Kohli, Thomas Chittenden, Julianto Setiady
  • BIPARATOPIC FR-ALPHA ANTIBODIES AND IMMUNOCONJUGATES
    Publication number: 20230085779
    Abstract: The present disclosure provides biparatopic antibodies comprising polypeptides that bind to folate receptor alpha (FR?) compositions comprising such biparatopic antibodies. In a specific aspect, the biparatopic antibodies bind to FR? and modulate FR? activity. The present disclosure also provides methods for treating disorders, such as cancer, by administering a biparatopic antibody that specifically binds to FR? and modulates FR? activity.
    Type: Application
    Filed: June 10, 2022
    Publication date: March 23, 2023
    Inventors: Olga AB, Neeraj Kohli, Thomas Chittenden, Julianto Setiady
  • ANTI-CD123 ANTIBODIES AND CONJUGATES AND DERIVATIVES THEREOF
    Publication number: 20220372152
    Abstract: The present invention generally relates to antibodies, antigen-binding fragments thereof, polypeptides, and immunoconjugates that bind to CD123 antigen (the ? chain of the interleukine 3 receptor, or IL-3R?). The present invention also relates to methods of using such CD123-binding molecules for diagnosing and treating diseases, such as B-cell malignancies.
    Type: Application
    Filed: April 1, 2022
    Publication date: November 24, 2022
    Inventors: Yelena Kovtun, Daniel J. Tavares, Lingyun Rui, Thomas Chittenden
  • Biparatopic FR-? antibodies and immunoconjugates
    Patent number: 11396543
    Abstract: The present disclosure provides biparatopic antibodies comprising polypeptides that bind to folate receptor alpha (FR?) compositions comprising such biparatopic antibodies. In a specific aspect, the biparatopic antibodies bind to FR? and modulate FR? activity. The present disclosure also provides methods for treating disorders, such as cancer, by administering a biparatopic antibody that specifically binds to FR? and modulates FR? activity.
    Type: Grant
    Filed: April 28, 2020
    Date of Patent: July 26, 2022
    Assignee: ImmunoGen, Inc.
    Inventors: Olga Ab, Neeraj Kohli, Thomas Chittenden, Julianto Setiady
  • Anti-CD123 antibodies and conjugates and derivatives thereof
    Patent number: 11332535
    Abstract: The present invention generally relates to antibodies, antigen-binding fragments thereof, polypeptides, and immunoconjugates that bind to CD123 antigen (the ? chain of the interleukine 3 receptor, or IL-3R?). The present invention also relates to methods of using such CD123-binding molecules for diagnosing and treating diseases, such as B-cell malignancies.
    Type: Grant
    Filed: October 22, 2020
    Date of Patent: May 17, 2022
    Assignee: IMMUNOGEN, INC.
    Inventors: Yelena Kovtun, Daniel J. Tavares, Lingyun Rui, Thomas Chittenden
  • EPCAM ANTIBODIES, ACTIVATABLE ANTIBODIES, AND IMMUNOCONJUGATES, AND USES THEREOF
    Publication number: 20210403594
    Abstract: The disclosure generally relates to antibodies and antibody fragments that specifically bind human EpCAM, EpCAM activatable antibodies, and immunoconjugates thereof, as well as, methods of making and using the antibodies, antibody fragments, activatable antibodies, and immunoconjugates, for the diagnosis and treatment of diseases such as cancer.
    Type: Application
    Filed: October 23, 2019
    Publication date: December 30, 2021
    Inventors: Yimao LIU, Stuart W. HICKS, Cynthia J. GUIDI, Neeraj KOHLI, Thomas CHITTENDEN, John LAMBERT, Madan PAIDHUNGAT, Jason Gary SAGERT, Kimberly Ann TIPTON, Chanty Mariategue CHAN, Ellaine Anne Mariano FOX
  • ANTI-CD123 ANTIBODIES AND CONJUGATES AND DERIVATIVES THEREOF
    Publication number: 20210147560
    Abstract: The present invention generally relates to antibodies, antigen-binding fragments thereof, polypeptides, and immunoconjugates that bind to CD123 antigen (the ? chain of the interleukine 3 receptor, or IL-3R?). The present invention also relates to methods of using such CD123-binding molecules for diagnosing and treating diseases, such as B-cell malignancies.
    Type: Application
    Filed: October 22, 2020
    Publication date: May 20, 2021
    Inventors: Yelena Kovtun, Daniel J. Tavares, Lingyun Rui, Thomas Chittenden
  • Anti-CD123 antibodies and conjugates and derivatives thereof
    Patent number: 10919969
    Abstract: The present invention generally relates to antibodies, antigen-binding fragments thereof, polypeptides, and immunoconjugates that bind to CD123 antigen (the ? chain of the interleukine 3 receptor, or IL-3R?). The present invention also relates to methods of using such CD123-binding molecules for diagnosing and treating diseases, such as B-cell malignancies.
    Type: Grant
    Filed: August 3, 2017
    Date of Patent: February 16, 2021
    Assignee: IMMUNOGEN, INC.
    Inventors: Yelena Kovtun, Daniel J. Tavares, Lingyun Rui, Thomas Chittenden
  • Anti-CD123 antibodies and conjugates and derivatives thereof
    Patent number: 10875925
    Abstract: The present invention generally relates to antibodies, antigen-binding fragments thereof, polypeptides, and immunoconjugates that bind to CD123 antigen (the ? chain of the interleukine 3 receptor, or IL-3R?). The present invention also relates to methods of using such CD123-binding molecules for diagnosing and treating diseases, such as B-cell malignancies.
    Type: Grant
    Filed: January 31, 2020
    Date of Patent: December 29, 2020
    Assignee: IMMUNOGEN, INC.
    Inventors: Yelena Kovtun, Daniel J. Tavares, Lingyun Rui, Thomas Chittenden
  • BIPARATOPIC FR-ALPHA ANTIBODIES AND IMMUNOCONJUGATES
    Publication number: 20200362029
    Abstract: The present disclosure provides biparatopic antibodies comprising polypeptides that bind to folate receptor alpha (FR?) compositions comprising such biparatopic antibodies. In a specific aspect, the biparatopic antibodies bind to FR? and modulate FR? activity. The present disclosure also provides methods for treating disorders, such as cancer, by administering a biparatopic antibody that specifically binds to FR? and modulates FR? activity.
    Type: Application
    Filed: April 28, 2020
    Publication date: November 19, 2020
    Inventors: Olga AB, Neeraj KOHLI, Thomas CHITTENDEN, Julianto SETIADY
  • ANTI-CD123 ANTIBODIES AND CONJUGATES AND DERIVATIVES THEREOF
    Publication number: 20200239580
    Abstract: The present invention generally relates to antibodies, antigen-binding fragments thereof, polypeptides, and immunoconjugates that bind to CD123 antigen (the ? chain of the interleukine 3 receptor, or IL-3R?). The present invention also relates to methods of using such CD123-binding molecules for diagnosing and treating diseases, such as B-cell malignancies.
    Type: Application
    Filed: January 31, 2020
    Publication date: July 30, 2020
    Inventors: YELENA KOVTUN, DANIEL J. TAVARES, LINGYUN RUI, THOMAS CHITTENDEN
  • Methods of use of anti-CD123 antibodies and antigen-binding fragments thereof
    Patent number: 10442865
    Abstract: The present invention generally relates to antibodies, antigen-binding fragments thereof, polypeptides, and immunoconjugates that bind to CD123 antigen (the a chain of the interleukine 3 receptor, or IL-3R?). The present invention also relates to methods of using such CD123-binding molecules for diagnosing and treating diseases, such as B-cell malignancies.
    Type: Grant
    Filed: April 19, 2018
    Date of Patent: October 15, 2019
    Assignee: IMMUNOGEN, INC.
    Inventors: Yelena Kovtun, Daniel J. Tavares, Lingyun Rui, Thomas Chittenden
  • ANTI-CD123 ANTIBODIES AND CONJUGATES AND DERIVATIVES THEREOF
    Publication number: 20180355047
    Abstract: The present invention generally relates to antibodies, antigen-binding fragments thereof, polypeptides, and immunoconjugates that bind to CD123 antigen (the a chain of the interleukine 3 receptor, or IL-3R?). The present invention also relates to methods of using such CD123-binding molecules for diagnosing and treating diseases, such as B-cell malignancies.
    Type: Application
    Filed: April 19, 2018
    Publication date: December 13, 2018
    Inventors: Yelena Kovtun, Daniel J. Tavares, Lingyun Rui, Thomas Chittenden
  • Anti-CD123 antibodies and conjugates and derivatives thereof
    Patent number: 10077313
    Abstract: The present invention generally relates to antibodies, antigen-binding fragments thereof, polypeptides, and immunoconjugates that bind to CD123 antigen (the ? chain of the interleukine 3 receptor, or IL-3R?). The present invention also relates to methods of using such CD123-binding molecules for diagnosing and treating diseases, such as B-cell malignancies.
    Type: Grant
    Filed: June 28, 2016
    Date of Patent: September 18, 2018
    Assignee: IMMUNOGEN, INC.
    Inventors: Yelena Kovtun, Daniel Tavares, Lingyun Rui, Thomas Chittenden
  • MET ANTIBODIES AND IMMUNOCONJUGATES AND USES THEREOF
    Publication number: 20180230218
    Abstract: MET is a receptor tyrosine kinase found on the surface of tumor cells. The present invention includes anti-MET antibodies, forms and fragments, having superior physical and functional properties; immunoconjugates, compositions, diagnostic reagents, methods for inhibiting growth, therapeutic methods, improved antibodies and cell lines; and polynucleotides, vectors and genetic constructs encoding same.
    Type: Application
    Filed: January 3, 2018
    Publication date: August 16, 2018
    Inventors: Thomas Chittenden, Jutta Deckert, Stuart William Hicks, Katharine C. Lai, Peter U. Park, Lingyun Rui, Daniel J. Tavares, Neeraj Kohli
  • ANTI-CD123 ANTIBODIES AND CONJUGATES AND DERIVATIVES THEREOF
    Publication number: 20180079819
    Abstract: The present invention generally relates to antibodies, antigen-binding fragments thereof, polypeptides, and immunoconjugates that bind to CD123 antigen (the ? chain of the interleukine 3 receptor, or IL-3R?). The present invention also relates to methods of using such CD123-binding molecules for diagnosing and treating diseases, such as B-cell malignancies.
    Type: Application
    Filed: August 3, 2017
    Publication date: March 22, 2018
    Inventors: Yelena Kovtun, Daniel J. Tavares, Lingyun Rui, Thomas Chittenden
  • ANTI-CD123 ANTIBODIES AND CONJUGATES AND DERIVATIVES THEREOF
    Publication number: 20170029514
    Abstract: The present invention generally relates to antibodies, antigen-binding fragments thereof, polypeptides, and immunoconjugates that bind to CD123 antigen (the ? chain of the interleukine 3 receptor, or IL-3R?). The present invention also relates to methods of using such CD123-binding molecules for diagnosing and treating diseases, such as B-cell malignancies.
    Type: Application
    Filed: June 28, 2016
    Publication date: February 2, 2017
    Inventors: Yelena Kovtun, Daniel Tavares, Lingyun Rui, Thomas Chittenden
  • Novel EGFR-Binding Molecules and Immunoconjugates Thereof
    Publication number: 20160060345
    Abstract: Novel anti-cancer agents, including, but not limited to, antibodies and immunoconjugates, that bind to EGFR are provided. Methods of using the agents, antibodies, or immunoconjugates, such as methods of inhibiting tumor growth are further provided.
    Type: Application
    Filed: August 7, 2015
    Publication date: March 3, 2016
    Inventors: Julianto SETIADY, Peter U. Park, Lingyun Rui, Thomas Chittenden, Gillian Payne
  • Non-Antagonistic EGFR-Binding Molecules and Immunoconjugates Thereof
    Publication number: 20160017053
    Abstract: Novel anti-cancer agents, including, but not limited to, antibodies and immunoconjugates, that bind to EGFR are provided. Methods of using the agents, antibodies, or immunoconjugates, such as methods of inhibiting tumor growth are further provided.
    Type: Application
    Filed: May 8, 2015
    Publication date: January 21, 2016
    Applicant: ImmunoGen, Inc.
    Inventors: Julianto SETIADY, Rajeeva Singh, Peter U. Park, Lingyun Rui, Thomas Chittenden